us
food
drug
administr
approv
new
antibiot
past
year
antibiot
discov
twentieth
centuri
recent
prolifer
new
antibiot
made
select
diffi
cult
select
antibiot
depend
clinic
fi
nding
like
caus
organ
laboratori
confi
rmation
pharmacokinet
drug
purpos
chapter
put
hand
ophthalmologist
concis
approach
select
topic
system
antimicrobi
agent
manag
infect
eye
would
provid
practic
concis
object
inform
antimicrobi
agent
use
treatment
infect
eye
inform
use
rapid
refer
eye
care
practition
use
antibiot
ocular
infect
prevent
preemptiv
cur
prophylaxi
guidelin
proper
use
antimicrobi
agent
ophthalmolog
outlin
tabl
dramat
decreas
incid
classic
infecti
diseas
due
larg
fi
rst
mass
vaccin
erad
certain
infecti
diseas
smallpox
second
implement
rigor
public
health
measur
mani
countri
third
introduct
newli
discov
antimicrobi
agent
fi
rst
decad
twentyfi
rst
centuri
infecti
diseas
continu
seriou
caus
visual
loss
mortal
morbid
rest
laurel
overcom
classic
infect
rather
prepar
confront
microorgan
emerg
degrad
ecosystem
well
bacteria
becom
increasingli
antibiot
resist
sever
new
infecti
agent
recent
identifi
ed
caus
diseas
man
tabl
chemic
use
earli
seventeenth
centuri
treat
infecti
diseas
quinin
use
malaria
emetin
use
amebiasi
antibiot
howev
caus
harm
well
good
erlich
germani
introduc
concept
select
toxic
chemic
show
possibl
use
antibiot
toxic
microorgan
harm
host
fleme
record
observ
agar
plate
laboratori
contamin
penicillium
spp
free
bacteria
staphylococci
went
discov
penicillin
germani
domagk
describ
sulfonamid
win
nobel
prize
also
launch
new
era
antimicrobi
agent
howev
chain
florey
use
penicillin
treatment
streptococcu
pneumonia
infect
turn
point
manag
infecti
diseas
streptomycin
describ
late
tetracyclin
launch
earli
follow
chloramphenicol
later
follow
lincomycin
lincomycin
describ
systemat
analysi
soil
sampl
lincoln
nebraska
unit
state
name
state
capit
citi
lincoln
produc
strain
streptomyc
lincolnensi
discoveri
extens
soil
sampl
conduct
worldwid
isol
identifi
antibioticproduc
organ
mani
differ
type
gener
antibiot
import
therefor
identifi
use
ophthalmolog
paramount
import
select
right
antibiot
treat
ocular
infect
fundament
identifi
cation
organ
respons
infect
initi
select
antibiot
treatment
ocular
infect
base
frequent
encount
organ
pharmacokinet
antibiot
dosag
cost
great
stumbl
block
safe
effect
antibiot
therapi
resist
toxic
two
factor
must
alway
taken
account
choos
antibiot
cost
anoth
factor
one
often
overlook
import
awar
fact
antibiot
expens
use
antibiot
treatment
ocular
infect
initi
whenev
patient
infect
microbi
natur
organ
suscept
antibiot
prescrib
patient
histori
eye
examin
consist
diagnosi
microbi
infect
ocular
specimen
stain
cultur
molecular
diagnosi
eg
pcr
obtain
initi
therapi
sent
immedi
laboratori
etiolog
organ
caus
infect
identifi
ed
seriou
infect
treatment
may
start
empir
laboratori
result
obtain
select
antibiot
base
suscept
organ
advers
effect
penetr
affect
tissu
cost
discrep
result
laboratori
sensit
test
patient
clinic
respons
care
evalu
advers
effect
use
antibiot
allerg
toxic
taken
account
select
administr
antibiot
agent
autotox
nephrotox
hepatotox
antibiot
discontinu
allerg
seriou
advers
reaction
occur
use
blood
level
monitor
system
antibiot
assess
whenev
indic
durat
therapi
depend
natur
infect
site
infect
less
week
rout
antibiot
given
dosag
level
allow
penetr
antibiot
desir
infect
site
within
safe
margin
shortest
period
time
erad
offend
agent
possibl
superinfect
alway
kept
mind
antibiot
use
prolong
period
time
use
antibiot
combin
avoid
unless
organ
cultur
fi
nding
highli
suggest
infecti
etiolog
antibiot
prophylaxi
surgeri
use
care
antibiot
use
cover
gramneg
gramposit
organ
start
surgeri
discontinu
immedi
follow
surgeri
longterm
use
antibiot
avoid
instanc
patient
receiv
expens
therapi
fact
organ
respons
infect
sensit
much
cheaper
antibiot
combin
antibiot
agent
may
use
simultan
follow
condit
sever
devast
visionthreaten
ocular
infect
unknown
etiolog
lab
test
initi
determin
specifi
c
etiolog
agent
b
infect
caus
one
organ
c
emerg
resist
strain
bacteria
treatment
case
infect
caus
organ
known
respond
better
simultan
use
one
antibiot
toxoplasma
acanthamoeba
e
organ
cultur
clinic
fi
nding
highli
suggest
infecti
etiolog
although
antibiot
describ
either
bacteriostat
bactericid
less
use
classifi
cation
one
base
drug
mechan
action
name
affect
target
organ
system
classifi
cation
fi
rst
group
antibiot
inhibit
synthesi
cell
wall
second
group
inhibit
cell
membran
third
group
affect
ribosom
function
protein
synthesi
fourth
group
affect
nucleic
acid
synthesi
topic
antimicrobi
agent
use
ocular
infect
list
tabl
sever
antibiot
affect
cell
wall
organ
includ
penicillin
cephalosporin
gramicidin
bacitracin
bacteri
surviv
compromis
without
cell
wall
cell
wall
protect
bacteria
environment
noxiou
agent
maintain
intracellular
milieu
thick
bacteri
cell
wall
vari
gramposit
bacteria
thick
cell
wall
gramneg
bacteria
thin
cell
wall
intern
osmot
pressur
gramposit
organ
higher
gramneg
organ
gramposit
organ
particular
consider
risk
death
cell
wall
compromis
bacteri
cell
wall
contain
peptidoglycan
ligand
altern
pyranosid
residu
two
amino
sugar
n
acetylglucosamin
n
acetylmuram
acid
latter
found
mammalian
cell
crosslink
pentapeptid
chain
pentapeptid
crosslink
give
cell
wall
rigid
consequ
introduct
antimicrobi
agent
antibiot
interfer
crosslink
caus
cell
wall
weaken
organ
die
unlik
bacteria
mammalian
cell
cell
wall
select
target
exampl
select
toxic
penicillin
betalactam
antibiot
four
gener
penicillin
fi
rst
three
import
treatment
ocular
infect
fi
rstgener
penicillin
penicillin
g
penicillinaseresist
penicillin
two
type
methicillin
nafcillin
methicillin
use
treat
betalactamaseproduc
organ
methicillin
caus
interstiti
nephriti
longer
use
center
penicillin
use
specifi
calli
treat
ocular
infect
caus
streptococcu
neisseria
clostridium
spp
syphili
actinomyc
secondgener
penicillin
includ
ampicillin
amoxicillin
antibiot
slightli
broader
spectrum
fi
rst
gener
secondgener
penicillin
use
treat
ocular
infect
caus
haemophilu
speci
enterococci
thirdgener
penicillin
carbenicillin
ticarcillin
ticarcillin
combin
clavulan
acid
suicid
inhibitor
betalactamas
antibiot
occupi
receptor
site
gramneg
bacteria
make
activ
gramneg
bacteria
recent
carbenicillin
use
treat
pseudomona
infect
ticarcillin
replac
carbenicillin
may
use
combin
steril
intravitr
insert
design
releas
drug
period
aminoglycosid
fourth
group
penicillin
compris
mezlocillin
piperacillin
azlocillin
deriv
ampicillin
similar
carbenicillin
ticarcillin
antibiot
also
effect
gramneg
organ
greater
affi
niti
cell
wall
receptor
site
gramneg
organ
gramposit
organ
fourthgener
penicillin
limit
role
ophthalmolog
new
gener
antibiot
necessarili
better
effect
earlier
gener
gener
antibiot
play
specifi
c
role
specifi
c
indic
advantag
treatment
infect
caus
suscept
organ
organ
becom
resist
produc
betalactamas
enzym
disrupt
betalactam
ring
render
ineffect
order
counteract
antibiot
call
clavulan
acid
produc
streptomyc
spp
introduc
clavulan
acid
weak
antibiot
effect
bind
betalactamas
inhibit
effect
suicid
inhibit
clavulan
acid
uniqu
affi
niti
betalactamas
lead
deactiv
combin
clavulan
acid
exist
antibiot
constitut
new
gener
antibiot
new
therapeut
strategi
improv
effect
exist
antibiot
combin
mg
amoxicillin
mg
clavulan
acid
augmentin
effect
betalactamaseproduc
organ
haemophilu
streptococci
drug
use
treatment
presept
cellul
young
children
haemophilu
common
caus
similarli
combin
ticarcillin
clavulan
acid
timentin
cloxacillin
similar
clavulan
acid
timentin
strong
affi
niti
betalactamas
neutral
effect
sever
exampl
monobactam
antibiot
avail
impenem
meropenen
ectapenem
wide
antimicrobi
activ
impenen
effect
anaerob
gramposit
gramneg
organ
streptococcu
pneumonia
streptococcu
group
staphylococcu
aureu
streptococcu
faecali
haemophilu
infl
uenza
minimum
inhibitori
concentr
imipenem
haemophilu
infl
uenza
neisseria
spp
less
imipenem
also
effect
enterobacteriacea
pseudomona
acinetobact
calcoaceticu
imipenem
market
combin
silastin
silastin
inhibit
hydropeptidas
enzym
releas
brush
border
kidney
destroy
imipenem
consequ
cilastatin
prolong
halflif
imipenem
increas
concentr
imipenem
urin
imipenem
use
conjunct
cephalosporin
potenti
antagon
cephalosporin
import
group
account
antibiot
prescrib
hospit
tabl
cephalosporin
avail
mani
investig
advantag
cephalosporin
includ
broadspectrum
bactericid
select
toxic
cephalosporin
fi
rst
gener
effect
penicillinaseproduc
staphylococcu
aureu
disadvantag
cephalosporin
includ
low
csf
level
therefor
agent
recommend
treat
mening
limit
effect
enterococci
may
potenti
nephrotox
use
intraven
combin
aminoglycosid
fi
rst
gener
cephalosporin
introduc
one
antibiot
gener
cefazolin
group
antibiot
gener
cephalosporin
spectrum
fi
rstgener
cephalosporin
effect
gramposit
cocci
thirdor
fourthgener
cephalosporin
secondgener
cephalosporin
includ
cefuroxim
cefonicid
cefuroxim
treatment
choic
sinu
infect
use
intracamer
phacoemulsifi
cation
prevent
postop
endophthalm
unfortun
effect
pseudomona
enter
gramneg
organ
good
singl
drug
treatment
patient
sinus
orbit
cellul
cover
gramposit
cocci
staphylococci
streptococci
well
nonenter
gramneg
organ
also
effect
haemophilu
addit
cefuroxim
long
halflif
administ
intraven
twice
daili
unlik
cefamandol
cefuroxim
caus
bleed
tendenc
well
toler
disadvantag
cefuroxim
follow
activ
pseudomona
spp
enterococci
b
fragili
drug
rel
expens
cefaclor
oral
administr
thirdgener
cephalosporin
includ
ceftazidim
cefotaxim
ceftriaxon
ceftriaxon
drug
choic
treat
neisseria
gonorrhoea
current
strain
n
gonorrhoea
resist
penicillin
mani
resist
antimicrobi
agent
well
ceftriaxon
effect
infect
caus
neisseria
meningitidi
ceftriaxon
use
treatment
ocular
infect
caus
borrelia
leptospira
treponema
infect
caus
haemophilu
betalactamaseproduc
organ
advantag
ceftriaxon
includ
long
halflif
therefor
use
twice
daili
unlik
cephalosporin
administ
three
four
time
daili
make
costeffect
ceftriaxon
certain
disadvantag
includ
limit
valu
treatment
infect
caus
pseudomona
spp
except
combin
aminoglycosid
littl
effect
staphylococcu
aureu
may
prolong
bleed
time
fourth
fi
fth
gener
cephalosporin
far
limit
use
ocular
infect
teicoplanin
targocid
sanofi
aventi
ltd
glycopeptid
antibiot
similar
vancomycin
effect
gramposit
cocci
includ
methicillinresist
staphylococci
mrsa
drug
affect
cell
wall
synthesi
gramposit
bacteria
experi
ophthalm
infect
limit
oral
teicoplanin
shown
effect
treatment
clostridium
diffi
cile
associ
pseudomembran
coliti
fumagillin
use
treatment
corneal
microsporidiosi
compound
eyedrop
concentr
level
mgml
leiter
pharmaci
inc
park
ave
san
jose
ca
usa
telephon
also
shown
inhibit
angiogenesi
antibiot
inhibit
cell
membran
function
includ
polymyxin
b
amphotericin
b
colistin
imidazol
polyen
antibiot
amphotericin
b
polyen
act
fungi
affect
bacteri
cell
membran
polyen
bind
ergosterol
sterol
moieti
cell
membran
fungi
ergosterol
present
mammalian
bacteri
cell
membran
imidazol
act
fungi
differ
mode
action
polyen
imidazol
act
inhibit
ergosterol
synthesi
lead
disrupt
cell
membran
function
addit
imidazol
inhibit
cytochrom
c
peroxidas
allow
intracellular
accumul
hydrogen
peroxidas
lead
death
fungu
sinc
ergosterol
bind
site
amphotericin
b
use
imidazol
may
render
amphotericin
b
less
effect
compet
ergosterol
fungal
cell
membran
polymyxin
bind
phosphatidylethanolaminerich
membran
particularli
gramneg
organ
detergentlik
effect
disrupt
cell
membran
eventu
caus
death
organ
polymyxin
effect
treat
infect
caus
speci
pseudomona
well
certain
gramneg
organ
polymyxin
given
system
nephrotox
daptomycin
new
lipopeptid
antibiot
use
treatment
resist
gramposit
organ
produc
fungu
streptomyc
roseosporu
trade
name
cubicin
bind
bacteri
cell
membran
lead
depolar
loss
membran
function
daptomycin
may
also
act
inhibit
protein
synthesi
daptomycin
effect
gramposit
cocci
show
signifi
cant
corneal
penetr
follow
topic
eyedrop
rabbit
daptomycin
appear
safe
effect
given
intravitr
third
group
antibiot
consist
compound
inhibit
protein
synthesi
includ
chloramphenicol
tetracyclin
lincomycin
clindamycin
aminoglycosid
macrolid
use
extens
ocular
infect
bind
bacteri
ribosom
erythromycin
lead
inhibit
protein
synthesi
inhibit
protein
synthesi
also
achiev
tetracyclin
aminoglycosid
bind
portion
bacteri
ribosom
chloramphenicol
lincomycin
erythromycin
bind
portion
bacteri
ribosom
select
partial
antibiot
may
toxic
effect
human
cell
topic
chloramphenicol
wide
use
treat
ocular
surfac
infect
sever
report
fatal
aplast
anemia
follow
topic
administr
chloramphenicol
incid
idiosyncraci
chloramphenicol
high
nonetheless
larg
number
patient
given
topic
chloramphenicol
case
fatal
aplast
anemia
occur
situat
use
certain
antibiot
neither
ideal
appropri
approxim
staphylococci
isol
ocular
infect
resist
erythromycin
erythromycin
consid
drug
choic
treatment
infect
caus
organ
fusid
acid
anoth
antibiot
group
help
treatment
staphylococc
blephar
recov
staphylococc
isol
ocular
infect
site
assess
sensit
differ
antibiot
vancomycin
found
effect
antibiot
type
staphylococci
includ
staphylococcu
epidermidi
staphylococcu
aureu
result
show
strain
epidermidi
sensit
fusid
acid
sensit
bacitracin
sensit
methicillin
gentamicin
erythromycin
chloramphenicol
unfortun
resist
strain
staphylococci
fusid
acid
start
appear
current
close
ocular
isol
staphylococci
sensit
fusid
acid
topic
use
antibiot
chloramphenicol
less
effect
carri
risk
system
advers
effect
chloramphenicol
antibiot
consid
narrow
spectrum
mani
organ
resist
carri
risk
aplast
anemia
vital
chloramphenicol
prescrib
absolut
necessari
exampl
treat
strain
haemophilu
resist
antibiot
vancomycin
valuabl
antibiot
use
care
wide
inappropri
use
may
lead
emerg
resist
strain
addit
nephrotox
like
increas
system
vancomycin
combin
gentamicin
antagon
tetracyclin
use
combin
quinolon
erythromycin
betalactam
antibiot
betalactam
antibiot
use
combin
tetracyclin
erythromycin
chloramphenicol
sinc
latter
inhibit
ribosom
function
interfer
effect
betalactam
antibiot
azithromycin
macrolid
antibiot
belong
azalid
group
shown
highli
effect
chlamydi
infect
well
gramposit
bacteria
azithromycin
long
elimin
life
reach
h
azithromycin
found
effect
treatment
genit
chlamydia
singl
dose
suffi
cient
erad
azithromycin
also
effect
treatment
trachoma
cours
repeat
cours
azithromycin
requir
chronic
activ
case
trachoma
drug
high
intracellular
concentr
macrophag
polymorphonuclear
cell
follow
singl
oral
dose
azithromycin
drug
remain
conjunctiva
minimum
inhibitori
concentr
mic
chlamydia
week
drug
current
avail
eyedrop
concentr
azyt
laboratoir
clermontferrand
franc
concentr
azasit
inspir
pharmaceut
inc
nc
usa
tear
concentr
topic
azithromycin
studi
follow
topic
administr
singl
dose
azithromycin
healthi
volunt
studi
prospect
random
doublemask
studi
total
healthi
volunt
normal
tear
function
includ
twentythre
subject
receiv
azithromycin
eyedrop
subject
receiv
azithromycin
eyedrop
subject
receiv
azithromycin
eyedrop
tear
collect
subject
seven
time
point
period
use
schirmer
strip
weigh
tear
sampl
tear
sampl
analyz
azithromycin
highperform
liquid
chromatographi
mass
spectrometri
hplcm
peak
azithromycin
note
min
instil
mean
concentr
remain
mgl
h
lateonset
increas
tear
concentr
azithromycin
note
h
may
explain
known
azithromycin
releas
tissu
storag
cell
anoth
studi
kuehn
cowork
measur
concentr
azithromycin
clarithromycin
rabbit
corneal
tissu
follow
topic
applic
mgml
azithromycin
mgml
clarithromycin
shown
topic
azithromycin
concentr
higher
corneal
tissu
clarithromycin
azithromycin
use
treatment
chlamydi
conjunct
trachoma
kerat
due
mycobacterium
chelona
chronic
blephar
topic
azithromycin
use
treatment
blephar
cornea
expos
desicc
show
signifi
cant
increas
azithromycin
tissu
level
compar
normal
eye
follow
topic
applic
azithromycin
eyedrop
appear
dryness
may
increas
tissu
absorpt
cornea
linezolid
zyvox
synthet
antibiot
member
oxazolidinon
use
treatment
seriou
infect
caus
gramposit
bacteria
linezolid
inhibit
protein
synthesi
appear
work
disrupt
translat
messeng
rna
protein
ribosom
linezolid
bind
subunit
ribosom
shown
linezolid
activ
gramposit
bacteria
includ
streptococci
vancomycinresistantenterococci
methicillinresistantstaphylococcu
aureu
mrsa
main
indic
linezolid
infect
skin
soft
tissu
pneumonia
drug
avail
unit
state
unit
kingdom
name
zyvox
european
countri
name
zyvoxid
hand
canada
mexico
drug
known
zyvixam
gener
drug
avail
india
name
linospan
cipla
linezolid
oxazolidinon
antibiot
protein
synthesi
inhibitor
resist
linezolid
bacteria
remain
low
linezolid
proven
safe
effect
infect
due
suscept
organ
us
food
drug
associ
approv
linezolid
april
consid
bacteriostat
agent
main
indic
linezolid
treatment
sever
infect
caus
gramposit
bacteria
resist
antibiot
narrow
spectrum
therefor
remain
reserv
antibiot
case
sever
infect
due
resist
bacteria
linezolid
associ
clostridium
diffi
cile
associ
diarrhea
pseudomembran
coliti
longterm
use
linezolid
may
lead
bone
marrow
suppress
thrombocytopenia
fourth
group
antibiot
quinolon
compris
antibiot
inhibit
nucleic
acid
synthesi
pyrimethamin
interfer
synthesi
hydrofol
import
build
block
bacteri
dna
drug
use
treatment
toxoplasma
rifamycin
interfer
nucleic
acid
synthesi
inhibit
rnadepend
dna
polymeras
sulfonamid
synergist
trimethoprim
combin
system
use
fluoroquinolon
fl
uorin
substitut
posit
quinolon
molecul
addit
substitut
posit
posit
markedli
affect
antimicrobi
effi
caci
well
penetr
alter
substanti
improv
antimicrobi
effect
gramposit
well
gramneg
organ
addit
improv
solubl
ophthalm
solut
norfl
oxacin
fi
rst
fl
uoroquinolon
use
topic
ocular
infect
primarili
gramneg
activ
includ
antipseudomon
activ
well
limit
gramposit
activ
regul
dna
supercoil
essenti
dna
transcript
replic
supercoil
dna
molecul
coil
shorten
molecul
dna
helix
must
unwind
permit
proper
function
enzymat
machineri
involv
process
topoisomeras
serv
maintain
transcript
replic
dna
type
type
ii
topoisomeras
cut
one
strand
two
strand
dna
respect
underli
mechan
action
revers
trap
dna
gyras
topoisomeras
ii
topoisomeras
ivdna
complex
complex
format
follow
revers
inhibit
dna
synthesi
fl
uoroquinolon
concentr
increas
cell
death
occur
doublestrand
dna
break
releas
trap
gyras
andor
topoisomeras
iv
complex
mani
gramneg
bacteria
resist
aris
primarili
mutat
gyras
protein
gramposit
bacteria
primari
resist
occur
via
mutat
topoisomeras
iv
addit
effl
ux
pump
activ
pump
antibiot
bacteria
confer
multidrug
resist
via
membraneassoci
effl
ux
pump
gatifl
oxacin
moxifl
oxacin
resist
effl
ux
pump
chang
addit
confer
ad
anaerob
activ
gramneg
organ
may
also
exhibit
decreas
level
outer
membran
protein
facilit
diffus
bacteri
cell
drug
therebi
confer
addit
resist
work
concert
effl
ux
pump
last
two
mechan
confer
form
resist
overwhelm
higher
concentr
drug
fluoroquinolon
includ
moxifl
oxacin
gatifl
oxacin
besifl
oxacin
ciprofl
oxacin
fl
eroxacin
lomefl
oxacin
norfl
oxacin
ofl
oxacin
perfl
oxacin
temfl
oxacin
fl
uorosubstitut
quinolon
drug
potent
origin
nalidix
acid
structur
sever
quinolon
avail
topic
eyedrop
form
drug
good
vitro
action
mani
gramneg
gramposit
bacteria
action
anaerob
bacteria
remain
poor
mechan
action
quinolon
inhibit
dna
gyras
lomefl
oxacin
effect
gramneg
gramposit
organ
studi
chlamydia
trachomati
show
organ
moder
suscept
lomefl
oxacin
suscept
contrast
aminoglycosid
antibiot
activ
bacteri
cell
growth
phase
wherea
fl
uoroquinolon
rapidli
bactericid
vitro
vivo
growth
phase
secondari
phase
cell
growth
studi
carri
rabbit
model
reveal
lomefl
oxacin
readili
penetr
cornea
iri
ciliari
bodi
eye
reach
appreci
concentr
aqueou
penetr
occur
local
system
administr
penetr
shown
increas
presenc
melanin
fl
uoroquinolon
two
pka
valu
side
physiolog
ph
isoelectr
point
ph
union
fl
uoroquinolon
consid
lipophil
factor
thought
infl
uenc
consider
mechan
compound
penetr
bacteri
cell
membran
fluoroquinolon
approxim
protein
bound
valu
found
independ
drug
concentr
follow
oral
administr
lomefl
oxacin
drug
protein
bound
serum
evid
anim
studi
suggest
lomefl
oxacin
excret
unchang
kidney
although
small
concentr
metabolit
describ
notabl
drug
interact
occur
effect
fl
uoroquinolon
clearanc
theophyllin
plasma
concentr
theophyllin
rais
approxim
coadministr
perfl
oxacin
compar
enoxacin
ciprofl
oxacin
ofl
oxacin
nalidix
acid
increas
appar
plasma
level
theophyllin
interact
suppos
rise
parent
fl
uoroquinolon
metabolit
interact
produc
effect
hepat
isoenzym
result
reduc
capac
n
demethyl
theophyllin
oxometabolit
produc
metabol
elimin
lomefl
oxacin
drug
extens
excret
theophyllin
adjust
seem
necessari
patient
receiv
concomit
lomefl
oxacin
quinolon
interest
ophthalmolog
sever
avail
topic
form
levofl
oxacin
lomefl
oxacin
ciprofl
oxacin
ofl
oxacin
norfl
oxacin
moxifl
oxacin
gatifl
oxacin
besifl
oxacin
temefl
oxacin
avail
topic
use
effect
gramneg
organ
topic
form
ciprofl
oxacin
use
role
treatment
bacteri
kerat
caus
pseudomona
certain
fourthgener
quinolon
howev
limit
effi
caci
gramposit
cocci
quinolon
highli
effect
gramneg
organ
intermedi
activ
staphylococci
effect
group
b
streptococci
use
group
streptococci
streptococcu
pneumonia
anaerob
clearli
antibiot
select
effect
microorgan
make
unsuit
blind
shot
blanket
therapi
addit
system
fl
uoroquinolon
may
caus
cartilag
eros
children
use
children
pregnant
women
case
tetracyclin
antacid
may
decreas
absorpt
oral
quinolon
antibiot
choic
common
ocular
pathogen
shown
tabl
compound
dosag
intravitr
inject
antimicrobi
agent
shown
tabl
antimicrobi
therapi
tuberculosi
tabl
ocular
toxoplasmosi
also
list
tabl
confl
ict
interest
author
declar
confl
ict
interest
human
studi
carri
author
articl
anim
studi
carri
author
articl
azithromycin
mg
oral
twice
daili
week
clindamycin
mg
oral
q
h
week
trimethoprim
mgsulfameth
xazol
mg
twice
daili
week
visionthreaten
lesion
corticosteroid
use
vision
threaten
prednison
mg
mgkgday
gradual
taper
period
week
periocular
inject
triamcinolon
acetonid
mg
give
corticosteroid
day
initi
antimicrobi
agent
congenit
toxoplasmosi
pyrimethamin
mgkgday
oral
everi
day
sulfadiazin
mg
mgkgday
oral
two
divid
dose
week
corticosteroid
visionthreaten
lesion
mgkgday
oral
two
divid
dose
dosag
taper
progress
later
discontinu
folin
acid
mg
twice
weekli
treatment
pyrimethamin
adapt
modifi
ed
